ME Newswire / Businesswire

SAN FRANCISCO - Tuesday, December 10th 2013

PlayPhone’s Rapid Growth Underscores Position as World’s Third App Store

PlayPhone®, Inc., a global leader in mobile social gaming, today announced that it has entered into a partnership with Vivo, part of Telefonica Group, to bring PlayPhone’s leading edge social game store and global gaming network, branded PlayPhone Games, to Vivo customers. This partnership is the latest in a rapidly expanding list of key carrier partners including Verizon, Claro Brazil, SingTel and Sprint, to adopt PlayPhone’s turnkey social gaming platform. With the addition of Vivo, PlayPhone now reaches over 870 million mobile customers.

PlayPhone Games enables Vivo customers to discover, download and play a wide variety of the latest popular games with friends from around the world in a single app. It’s the first aggregated mobile games store for Vivo customers that offers secure direct carrier billing, and i ... Read more »

CHESHIRE, Conn - Tuesday, December 10th 2013 [ME NewsWire]

New Biomarker Data Support the Need for Chronic Terminal Complement Blockade with Soliris® (eculizumab) in Patients with aHUS ––

–– Data from the Largest Prospective Trial in Expanded Population of Adults with aHUS and First Prospective Trial in Pediatric Patients with aHUS Now Presented to Hematology Community––

–– New Registry Data Highlight Similar Disease Severity in PNH Patients With or Without a History of Transfusion ––

(BUSINESS WIRE) Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that researchers presented data from clinical trials demonstrating the clinical benefits of chronic Soliris® (eculizumab) treatment in patients with atypical hemolytic uremic syndrome (aHUS) as well as new patient registry data providing further insight into optimal care for patients with paroxysmal nocturnal hemoglobinuria (PNH) at the American Society of Hematology (ASH) 55th Annual Meeting a ... Read more »

INGELHEIM, Germany - Tuesday, December 10th 2013 [ME NewsWire]

    The efficacy and safety profile of Pradaxa® (dabigatran etexilate) was maintained regardless of patient characteristics1,2,3,4
    Pooled safety data favour Pradaxa® treatment over warfarin and provide further reassurance1-4
    The analysed patient characteristics included age, renal function, simultaneous use of anti-inflammatory drugs (NSAIDs) or low-dose acetylsalicylic acid (ASA) and the presence of cancer1-4
    Data also showed that taking commonly used NSAIDs or low-dose ASA with Pradaxa® did not increase the risk of bleeding1

(BUSINESS WIRE)-- For media outside of the US, the UK & Canada only

New data analyses show that the positive treatment effect (efficacy and safety profile) of Pradaxa® (dabigatran etexilate) 150mg twice daily was consistent in a wide range of patients with acute deep vein thrombosi ... Read more »

NEW YORK - Tuesday, December 10th 2013 [ME NewsWire]

(BUSINESS WIRE)-- Moody's Corporation (NYSE:MCO) announced today that it has again earned a score of 100 percent, the highest possible, on the Corporate Equality Index (CEI), a national benchmarking survey and report on corporate policies related to LGBT (lesbian, gay, bisexual and transgender) workplace equality administered by the Human Rights Campaign (HRC) Foundation.

Moody's ranking recognizes its status as a top employer for LGBT workplace equality, and its perfect score also qualified the company for inclusion in the HRC’s list of "Best Places to Work" for LGBT equality, for the second year in a row.

"Moody’s culture strongly values inclusion and respect for all of our employees around the world, and we are very proud to have once again earned the highest possible score in the Human Rights Campaign Corporate Equality Index," said Lisa Westlake, Senior Vice President and Chief Human Resources Officer at Moo ... Read more »